Basic Information
LncRNA/CircRNA Name | ANRIL |
Synonyms | CDKN2B-AS1, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p20AS |
Region | GRCh38_9:21994778-22121097 |
Ensemble | ENSG00000240498 |
Refseq | NR_003529 |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | Drug | |||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | glioma |
ICD-0-3 | NA |
Methods | qPCR, Western blot, Luciferase reporter assay, other |
Sample | glioma tissues and cell line (U251) |
Expression Pattern | up-regulated |
Function Description | lncRNA ANRIL was positively correlated with glioma grade and negatively correlated with miR-203a. lncRNA ANRIL silencing could induce anoikis and cell cycle arrest in G0/G1 phase, while regulating the activity of caspase-3/8/9 and the AKT signaling pathway, and the expression of tumor-related genes in the U251 cell line. miR-203a mimics could partially reverse these functions. |
Pubmed ID | 30197521 |
Year | 2018 |
Title | Effect of lncRNA ANRIL Silencing on Anoikis and Cell Cycle in Human Glioma via microRNA-203a |
External Links
Links for ANRIL | GenBank HGNC NONCODE |
Links for glioma | OMIM COSMIC |